Edward Jones analyst Logan Purk upgrades Qualcomm (NASDAQ:QCOM) from Hold to Buy.
Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –– New Data Presented Show Encouraging
